Dx & Vx Co., Ltd. (KOSDAQ:180400)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,275.00
-15.00 (-0.66%)
Last updated: Aug 7, 2025
-0.66%
Market Cap112.96B
Revenue (ttm)31.14B
Net Income (ttm)-47.30B
Shares Out49.22M
EPS (ttm)-1,162.81
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume149,619
Average Volume1,448,764
Open2,320.00
Previous Close2,290.00
Day's Range2,235.00 - 2,320.00
52-Week Range1,309.00 - 4,785.00
Beta0.01
RSI55.47
Earnings DateAug 14, 2025

About Dx & Vx

Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services; medical data; and funeral home operation services. It provides bacterial vaccine for respiratory disease; macular degeneration drug; atopy dermatitis ... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 2001
Employees 121
Stock Exchange KOSDAQ
Ticker Symbol 180400
Full Company Profile

Financial Performance

In 2024, Dx & Vx's revenue was 33.95 billion, a decrease of -17.69% compared to the previous year's 41.24 billion. Losses were -47.03 billion, 71.1% more than in 2023.

Financial Statements

News

There is no news available yet.